A recent clinical trial showed that Vapotherm’s (NYSE: VAPO) new IntellO2 module for its Precision Flow system greatly improved the chances of keeping premature babies in the target oxygenation range.
The prospective, multi-center, controlled, order-randomized crossover trial demonstrated that using the IntellO2 module helped clinicians maintain newborns in the physician-prescribed oxygen saturation range 80% of the time, compared with 49 % for manual control alone, the company said in a statement. The study was published in the Archives of Disease in Childhood: Fetal and Neonatal Edition.
Get the full story on our sister site, Medical Design & Outsourcing.
The post Vapotherm touts automated oxygen controller in preemie study appeared first on MassDevice.
from MassDevice https://ift.tt/2QEYaHh
Cap comentari:
Publica un comentari a l'entrada